期刊
BRITISH JOURNAL OF CANCER
卷 100, 期 1, 页码 1-7出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6604767
关键词
angiogenesis; vascular endothelial growth factor; angiogenesis inhibitors; ovarian neoplasms; biomarkers; adverse effects
类别
资金
- Medical Research Council [G0601746, G0902173] Funding Source: Medline
- Medical Research Council [G0601746] Funding Source: researchfish
- MRC [G0601746] Funding Source: UKRI
Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据